Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

Successful solid organ transplantation reflects meticulous attention to the details of
immunosuppression, balancing risks for graft rejection against risks for infection. The “net …

The long-term management of maintenance immunosuppression in kidney transplant
recipients remains complex. The vast majority of patients are treated with the calcineurin …

Abstract Tacrolimus (or FK506), a calcineurin inhibitor (CNI) introduced in field of
transplantation in the 1990s, is the cornerstone of most immunosuppressive regimens in …

TRANSFORM (TRANSplant eFficacy and safety Outcomes with an eveRolimus-based
regiMen) was a 24-month, prospective, open-label trial in 2037 de novo renal transplant …

Background. The safety profiles of standard therapy versus everolimus with reduced-
exposure calcineurin inhibitor (CNI) therapy using contemporary protocols in de novo kidney …

The kidney is a vital organ that regulates the bodily fluid and electrolyte homeostasis via
tailored urinary excretion. Kidney injuries that cause severe or progressive chronic kidney …

This is a randomized trial (ATHENA study) in de novo kidney transplant patients to compare
everolimus versus mycophenolic acid (MPA) with similar tacrolimus exposure in both …

Genetic and epigenetic alterations have been under concentrated investigations for many
years in order to unearth the molecules regulating human cancer pathogenesis. However …

Although the gold standard of monitoring kidney transplant function relies on glomerular
filtration rate (GFR), little is known about GFR trajectories after transplantation, their …